Get the free weekly contract digest
The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.
New new contracts, summarized for you
No login, no app to check — it comes to you
See who's moving and how much in your market
Lindy Biosciences Enters Licensing and Collaboration Agreement With Novartis for Multi-target Drug Delivery Innovation
Contract Type
agreement
MorrisvilleBiotechnologyDescription
Lindy Biosciences has announced a multi-target exclusive global licensing agreement and strategic collaboration with Novartis Pharma AG, focusing on transitioning select innovative medicines to self-administered subcutaneous injections using Lindy Biosciences’ proprietary technology. The collaboration aims to increase the maximum dose that can be administered in a single subcutaneous injection, potentially reducing healthcare costs and improving patient comfort and treatment compliance.